CA3181427A1 - Mitochondrial-derived peptides and analogs thereof for use as a therapy for age-related diseases including cancer - Google Patents

Mitochondrial-derived peptides and analogs thereof for use as a therapy for age-related diseases including cancer

Info

Publication number
CA3181427A1
CA3181427A1 CA3181427A CA3181427A CA3181427A1 CA 3181427 A1 CA3181427 A1 CA 3181427A1 CA 3181427 A CA3181427 A CA 3181427A CA 3181427 A CA3181427 A CA 3181427A CA 3181427 A1 CA3181427 A1 CA 3181427A1
Authority
CA
Canada
Prior art keywords
mitochondrial
seq
nosh
cancer
derived peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3181427A
Other languages
English (en)
French (fr)
Inventor
Pinchas Cohen
Kelvin YEN
Su-Jeong Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of CA3181427A1 publication Critical patent/CA3181427A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3181427A 2020-05-15 2021-05-14 Mitochondrial-derived peptides and analogs thereof for use as a therapy for age-related diseases including cancer Pending CA3181427A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063025495P 2020-05-15 2020-05-15
US63/025,495 2020-05-15
PCT/US2021/032641 WO2021231988A2 (en) 2020-05-15 2021-05-14 Mitochondrial-derived peptides and analogs thereof for use as a therapy for age-related diseases including cancer

Publications (1)

Publication Number Publication Date
CA3181427A1 true CA3181427A1 (en) 2021-11-18

Family

ID=78525101

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3181427A Pending CA3181427A1 (en) 2020-05-15 2021-05-14 Mitochondrial-derived peptides and analogs thereof for use as a therapy for age-related diseases including cancer

Country Status (8)

Country Link
US (1) US12577281B2 (https=)
EP (1) EP4149511B1 (https=)
JP (1) JP2023528220A (https=)
KR (1) KR20230019112A (https=)
CN (1) CN115697373A (https=)
CA (1) CA3181427A1 (https=)
MX (1) MX2022014123A (https=)
WO (1) WO2021231988A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115697373A (zh) 2020-05-15 2023-02-03 南加利福尼亚大学 线粒体衍生肽和其类似物作为包括癌症的年龄相关性疾病的治疗的用途
WO2026021591A1 (zh) * 2024-07-26 2026-01-29 南京安吉生物科技有限公司 一种新型调节能量代谢的微肽mp29及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9419553D0 (en) * 1994-09-27 1994-11-16 Univ Bristol Polypeptides and their use in the treatment of auto-immune disease
JP2004520803A (ja) 2000-04-21 2004-07-15 コリクサ コーポレイション 尋常性挫瘡の治療および診断のための組成物および方法
CN101586112B (zh) * 2009-06-19 2011-06-22 中国科学院上海有机化学研究所 诺丝七肽的生物合成基因簇
US20140296139A1 (en) * 2013-03-15 2014-10-02 The Regents Of The University Of California Mitochondrial-derived peptide mots3 regulates metabolism and cell survival
EP3022222A4 (en) * 2013-07-18 2017-06-07 Eutropics Pharmaceuticals, Inc. Differential bh3 mitochondrial profiling
BR112016027911A2 (pt) * 2014-05-28 2017-10-24 Evogene Ltd polinucleotídeos isolados, polipeptídeos e métodos de uso dos mesmos para aumento da tolerância ao estresse abiótico, biomassa e produção da planta
CA3026458A1 (en) * 2016-06-24 2017-12-28 University Of Southern California Mentsh analogs as therapeutics for diabetes, obesity, and their associated diseases and complications
US11208443B2 (en) * 2017-02-14 2021-12-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. NAF-1 derived peptides and uses thereof
CN115697373A (zh) 2020-05-15 2023-02-03 南加利福尼亚大学 线粒体衍生肽和其类似物作为包括癌症的年龄相关性疾病的治疗的用途

Also Published As

Publication number Publication date
WO2021231988A3 (en) 2022-02-24
WO2021231988A2 (en) 2021-11-18
KR20230019112A (ko) 2023-02-07
CN115697373A (zh) 2023-02-03
US12577281B2 (en) 2026-03-17
EP4149511B1 (en) 2026-03-25
MX2022014123A (es) 2022-12-08
JP2023528220A (ja) 2023-07-04
US20230167161A1 (en) 2023-06-01
EP4149511A2 (en) 2023-03-22
EP4149511A4 (en) 2024-05-22

Similar Documents

Publication Publication Date Title
DK2479275T3 (en) HLA-A * 1101-restricted WT1 peptide or pharmaceutical composition comprising this
EP2385117B1 (en) HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
US11760783B2 (en) MENTSH analogs as therapeutics for diabetes, obesity, and their associated diseases and complications
CN109438570B (zh) 肿瘤相关基因fgfr3突变短肽及其应用
EP4149511B1 (en) Mitochondrial-derived peptides and analogs thereof for use as a therapy for age-related diseases including cancer
AU2019352354B2 (en) Prophylactic or therapeutic drug for benign tumor
HK40085747A (en) Mitochondrial-derived peptides and analogs thereof for use as a therapy for age-related diseases including cancer
CN105348380A (zh) 犬成纤维细胞生长因子21及其在治疗犬内分泌疾病中的用途
EP3080296B1 (en) A method of predicting a response to an anti-tumor treatment
HK1225067A1 (en) Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
HK1225067A (en) Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
HK1225067B (en) Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
HK1221252B (en) Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
HK1133671A (en) Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
HK1173186A (en) Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251106

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260204